doi: 10.1007/BF00492251 14 FujitaYAsadiAYangGKKwokYNKiefferTJ
Trulicity (dulaglutide) is a GLP-1 receptor agonist manufactured by Eli Lilly: FDA approval: 2014 for Type 2 diabetes Dosing: Weekly subcutaneous injection (0.75mg, 1.5mg, 3.0mg, or 4.5mg) Device: Single-use, disposable pen with hidden needle Mechanism: Activates GLP-1 receptors to improve blood sugar control and reduce appetite Trulicity was one of the earlier weekly GLP-1 medications and gained popularity partly due to its user-friendly injection device
If we remove the methionine input in the model, the GSH concentration declines to a new steady-state 47% of normal
Gallbladder problems: GLP-1 agonists may increase the risk of gallstones and gallbladder inflammation, especially during rapid weight loss
Joshi, Anoop Misra, Ambrish Mithal, Banshi Saboo, Krishna G